Janssen Biotech, Inc.

Donna Klein

Steven Jacobs

Karyn O'Neil

Michael Diem

Linus Hyun

Ricardo Attar

Kristen Picha

Sheri Moores

Shalom Goldberg

Alastair King

Mark L Anderson

Tracy Spinka-Doms

Rosa Cardoso

Jinquan Luo

Sheng-Jiun Wu

Alexey Teplyakov

Francois Gaudet

Yingzhe Li

Theresa Marie McDevitt

Jill Marie Mooney

Glenn Mark Anderson

Ronan McDaid

Benjamin J Harman

Jennifer Nemeth-Seay

Leopoldo Luistro

Neeraj Kohli

Steven J Orcutt

Anderson Mark

Steven Pomerantz

Galla Chandra Rao

Mark Anderson

Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

EGFR and C-met fibronectin type III domain binding molecules

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Prostate specific membrane antigen binding fibronectin type iii domains

Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.

Anti-PSMA antibodies and uses thereof

EGFR and c-Met fibronectin type III domain binding molecules

Provided herein are isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

Prostate specific membrane antigen binding fibronectin type III domains

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered fibronectin type III domain binding molecules

EGFR and C-Met fibronectin type III domain binding molecules

Growing community of inventors

Spring House, PA, United States of America

Donna Klein